Infinity Pharmaceuticals (NASDAQ:INFI) has tumbled 68.4% during the past week and has dropped 68.53% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 68.02%. Infinity Pharmaceuticals (NASDAQ:INFI) has underperformed the index by 68.82% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Infinity Pharmaceuticals (NASDAQ:INFI): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.47 and $1.46 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.55. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.52, notching a gain of 2.70% for the day. The total traded volume was 4,134,084 . The stock had closed at $1.48 on the previous day.
The company shares have dropped -86.96% from its 1 Year high price. On Jun 23, 2015, the shares registered one year high at $11.75 and the one year low was seen on Jun 14, 2016. The 50-Day Moving Average price is $4.73 and the 200 Day Moving Average price is recorded at $6.03.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Perkins Adelene Q, director officer (President & CEO) of Infinity Pharmaceuticals, Inc., had unloaded 5,000 shares at an average price of $10.93 in a transaction dated on June 25, 2015. The total value of the transaction was worth $54,650.
Many analysts have stated their opinion on the company shares. Morgan Stanley downgrades its view on Infinity Pharmaceuticals (NASDAQ:INFI) according to the research report released by the firm to its investors. The shares have now been rated Equal-weight by the stock experts at the ratings house. Earlier, the shares had a rating of Overweight. Morgan Stanley lowers the price target from $11 per share to $1 per share on Infinity Pharmaceuticals . The rating by the firm was issued on June 15, 2016. Currently the company Insiders own 8.2% of Infinity Pharmaceuticals shares according to the proxy statements. Institutional Investors own 92.02% of Infinity Pharmaceuticals shares.
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.